Clinical Trial: A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07365319) titled 'A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.' on Jan. 22.

Brief Summary: This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.

Study Start Date: May 18, 2026

Study Type: INTERVENTIONAL

Condition: Non Small Cell Lung Cancer (Squamous or Non Squamous) Stage 4 NSCLC

Intervention: DRUG: EIK1001

EIK1001 is a Toll like receptor 7/8 (TLR 7/8) dual agonist

DRUG: Pembrolizumab (KEYTRUDA(R)...